Vaxxinity, Inc. Class A Common Stock/VAXX

$0.17

-15%
-
1D1W1MYTD1YMAX

About Vaxxinity, Inc. Class A Common Stock

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.

Ticker

VAXX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mei Mei Hu

Employees

57

Headquarters

Dallas, United States

VAXX Metrics

BasicAdvanced
$34.17M
Market cap
-
P/E ratio
-$0.45
EPS
-
Beta
-
Dividend rate
$34.17M
$3.10
$0.19
541.94K
1.888
98.904
113.118
-75.56%
-150.65%
-111.46%
2.548
2.548
24.67%

What the Analysts think about VAXX

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 1 analyst.
8,723.53% upside
High $15.00
Low $15.00
$0.17
Current price
$15.00
Average price target

VAXX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-11.3M
-13.74%
Profit margin
0%
-

VAXX Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q4 23
Actual
-
Expected
-$0.10
Surprise
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vaxxinity, Inc. Class A Common Stock stock?

Vaxxinity, Inc. Class A Common Stock (VAXX) has a market cap of $34.17M as of April 25, 2024.

What is the P/E ratio for Vaxxinity, Inc. Class A Common Stock stock?

The price to earnings (P/E) ratio for Vaxxinity, Inc. Class A Common Stock (VAXX) stock is 0 as of April 25, 2024.

Does Vaxxinity, Inc. Class A Common Stock stock pay dividends?

No, Vaxxinity, Inc. Class A Common Stock (VAXX) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next Vaxxinity, Inc. Class A Common Stock dividend payment date?

Vaxxinity, Inc. Class A Common Stock (VAXX) stock does not pay dividends to its shareholders.

What is the beta indicator for Vaxxinity, Inc. Class A Common Stock?

Vaxxinity, Inc. Class A Common Stock (VAXX) does not currently have a Beta indicator.

What is the Vaxxinity, Inc. Class A Common Stock stock price target?

The target price for Vaxxinity, Inc. Class A Common Stock (VAXX) stock is $15, which is 11438.46% above the current price of $0.13. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vaxxinity, Inc. Class A Common Stock stock

Buy or sell Vaxxinity, Inc. Class A Common Stock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing